Cortex Pharmaceuticals, Inc. (NYSE Amex: COR) announced that it has received notification from the NYSE Amex LLC indicating that, due to the Company’s non-compliance with...
Cortex Pharmaceuticals, Inc. (NYSE Amex (COR)) reported a net loss applicable to common stock of $3,243,000, or $0.06 per share for the quarter ended September 30, 2009 compared...
Cortex Pharmaceuticals, Inc. (NYSE Amex: COR) President and CEO, Mark A. Varney, Ph.D., will present at Rodman & Renshaw’s Eleventh Annual Healthcare Conference taking place...
Cortex Pharmaceuticals, Inc. (NYSE Amex (COR)) reported that it has received a delisting notification from the NYSE Amex LLC indicating that it has not accepted the Company’s...
Cortex Pharmaceuticals, Inc. (NYSE Amex: COR) reported a net loss applicable to common stock of $2,778,000, or $0.06 per share for the quarter ended June 30, 2009 compared with...
Cortex Pharmaceuticals, Inc. (NYSE Amex: COR) reported that it has entered into a definitive agreement with a single institutional investor related to a private placement of its...
Cortex Pharmaceuticals, Inc. (NYSE Amex: COR), a neuroscience company focused on developing novel AMPAKINE? drug therapies for neurological and psychiatric disorders, will web...
Cortex Pharmaceuticals, Inc. (NYSE Amex: COR) reported that it has received notice from the NYSE Amex LLC indicating that the company is not in compliance with certain of the...
Cortex Pharmaceuticals, Inc. (NYSE Amex: COR) reported a net loss of $3,168,000, or $0.07 per share for the quarter ended March 31, 2009 compared with a net loss of $4,371,000...
Cortex Pharmaceuticals, Inc. (NYSE Amex:COR) announced that it has completed the previously announced sale of shares of a newly-designated series of convertible preferred stock...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | DE |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관